DBVT Stock Forecast & Price Target

DBV Technologies is viewed favorably because Viaskin Peanut has reached a key regulatory inflection point, with BLA submission in children ages 4–7 and an FDA acceptance decision expected in 4Q26 or by the end of November, while Priority Review could accelerate a potential launch. The company’s fundamental upside is reinforced by strong regulatory positioning through Breakthrough Therapy Designation, an estimated ~90% POS in both the 4–7 and 1–3 year old populations, and projected peak sales of about $3B. Although 3Q26 showed a net loss of ~$64.6MM and cash of ~$165.7MM, runway into 3Q27 plus the view that Fareva’s CMC issues are not product-manufacturing defects supports confidence in execution and long-term value.

DBV Technologies is weighed down by repeated clinical and regulatory setbacks, including delays in BLA submissions for both children and toddlers and new adverse findings in the COMFORT-TODDLER study, which heighten uncertainty around Viaskin Peanut’s approvability and timing. Financially, the company remains loss-making, with 3Q26 OpEx of $66M versus a $49M estimate and $166M in cash expected to fund operations only into 3Q27, leaving continued dependence on external capital and the risk of dilution. Its outlook is further pressured by commercial uncertainty, since efficacy is variable, protection against peanut exposure is not easily measurable in real-world use, and emerging competitors could erode the opportunity in immunotherapy.